FFF Enterprises: BioSupply Trends Newsletter
Monday, July 16, 2018

Study Finds Asthma Treatments for Kids More Likely to Fail Without Flu Shot

 

In this Issue

•  IVIG/Albumin Supply Index
•  Open Market Pricing
•  New Products from FFF
•  Current Medicare
IVIG / SCIG Rates
•  Resources
•  Subscribe to IG Living and BioSupply Trends Quarterly
 

New research in the journal Pediatrics shows an annual influenza (flu) shot is crucial for children with asthma. [ read more ]

Tuberculosis Vaccine May Reverse Type 1 Diabetes

A recent study shows two injections of the bacillus Calmette-Guérin (BCG) vaccine (used to prevent tuberculosis) a few weeks apart may reverse the causes of type 1 diabetes over several years. [ read more ]

Study Shows Rapid Push for SCIG Therapy Is a Cost-Effective Alternative

A study conducted to compare the impact of pump and rapid push (syringe) subcutaneous immune globulin (SCIG) infusions on patients' life quality index showed the rapid push administration is preferred by some patients and is a cost-effective alternative to administration of larger volumes by pump once a week.
[ read more ]

With Snakebite Season in Summer, Medical Professionals Are Advised to Stock CroFab

Summer is snakebite season, and misunderstandings about proper treatment continue to subsist, not just among the general public, but among medical professionals as well. Only antivenoms can prevent or reverse most of the snakebite envenoming's effects, so it's important for healthcare facilities to have them in stock. Guidelines for stocking antivenom can be found at [ read more ]

Industry News

 
 

From Grifols

In May, Grifols' higher-potency rabies immune globulin (RIG), HyperRAB, was made available to healthcare providers. While HyperRAB has been on the market for 40 years, this improved RIG was approved by the U.S. Food and Drug Administration in April as a more effective and tolerable rabies treatment for patients. [ read more ]

From Incyte

The U.S. Food and Drug Administration has approved Incyte Corp.'s Olumiant (baricitinib) 2 mg once-daily oral medication to treat adults with moderately to severe active rheumatoid arthritis (RA). Olumiant is the second oral janus kinase inhibitor approved for RA in the U.S.  [ read more ]

From Shire

The U.S. Food and Drug Administration has approved Shire's Cinryze (C1 esterase inhibitor [human]) to prevent angioedema attacks in children 6 years and older with hereditary angioedema. [ read more ]

IVIG & Albumin Supply Index

 
 

Vaccines for International Travelers

It's officially summer, and that means that millions of Americans will be packing up and traveling to exciting international destinations. Thanks to rigorous immunization schedules here in the U.S., many diseases that once ran rampant, are now rare and preventable. However, these same diseases, such as measles or typhoid fever, are still very common in other parts of the world.

Therefore, before your patients leave on their next out-of-the-country trip, it's important for them to make sure their immunizations are up-to-date, especially since some countries require that visitors carry an International Certificate of Vaccination.

The U.S. Department of Health and Human Services recommends that anyone who plans to travel outside the U.S. visits their healthcare provider and receives the necessary vaccines for their country of destination. Vaccines should be administered four to six weeks prior to the departure date in order to ensure effectiveness.

For more information about available VACCINES, login to biosupply.fffenterprises.com.

These products can be ordered from FFF Enterprise's BioSupply Online Ordering System or by calling
Wow! Customer Care at (800) 843-7477.

Current Medicare IVIG / SCIG Rates

Rates per gram are effective July 1, 2018, through September 30, 2018.

 
Product J Codes ASP + 6%
(before sequester)
ASP + 4.3%*
(after sequester)
IVIG
Carimune NF J1566 $82.81 $81.48
Flebogamma J1572 $72.15 $71.00
Gammagard S/D J1566 $82.81 $81.48
Gammaplex J1557 $111.54 $109.75
Octagam J1568 $66.32 $65.25
Privigen J1459 $79.34 $78.07
SCIG
CUVITRU J1555 $135.01 $132.84
Hizentra J1559 $98.50 $96.92
HyQvia J1575 $145.38 $143.05
IVIG / SCIG
Gammagard Liquid J1569 $101.11 $99.49
Gammaked J1561 $82.42 $81.09
Gamunex-C J1561 $82.42 $81.09

*Reflects 2% sequestration reduction applied to 80% Medicare payment portion as required under Budget Control Act of 2011.

 

Resources

FFF customers may order the following complementary resources to help you with your practice:

•  IG Immune Globulin (Human)
•  Hyperimmune Globulins
•  Anti-Inhibitor, Factor VIIa & IX
•  Factor VIII & von Willebrand Factor
•  Seasonal Influenza Vaccine

Subscribe to IG Living

IG Living is the only magazine for the immune globulin (IG) community for patients who suffer from chronic illness and their caregivers.

Subscribe to BioSupply
Trends Quarterly

BioSupply Trends Quarterly magazine is the definitive source for industry trends, news and information for the biopharmaceuticals marketplace.

Home | About | Advertise | Subscribe | Contact – ©2018 FFF Enterprises, Inc.